Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Published inAnnals of the rheumatic diseases, vol. 70, no. 9, p. 1575-1580
Publication date2011
Abstract
Keywords
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived/therapeutic use
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/drug therapy/immunology
- Autoantibodies/blood
- Biological Markers/blood
- Drug Evaluation/methods
- Epidemiologic Methods
- Female
- Humans
- Male
- Middle Aged
- Peptides, Cyclic/immunology
- Prognosis
- Rheumatoid Factor/blood
- Treatment Failure
- Treatment Outcome
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
Affiliation
Research group
Citation (ISO format)
CHATZIDIONYSIOU, Katerina et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. In: Annals of the rheumatic diseases, 2011, vol. 70, n° 9, p. 1575–1580. doi: 10.1136/ard.2010.148759
Main files (1)
Article (Published version)
Identifiers
- PID : unige:25468
- DOI : 10.1136/ard.2010.148759
- PMID : 21571731
ISSN of the journal0003-4967
